Mar 30, 2020 SOURCE: PR NewsWire
AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director
NORTH CHICAGO, Ill., March 30, 2020 /PRNewswire/ -- AbbVie issued the following form today.
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1.
KEY
INFORMATION
Name of person dealing (Note 1)
Richard Gonzalez
---
Company dealt in
AbbVie Inc.
---
Class of relevant security to which the dealings being disclosed relate (Note 2) Common shares, par value
$0.01 per share
---
Date
of
dealing
25 March 2020
---
2. INTERESTS AND SHORT POSITIONS
(a)Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
---
(1) Relevant securities 377,893 Common Shares
(0.00025%)
---
(2)
Derivatives
(other
than
options) N/A
---
(3) Options and agreements to purchase/sell 1,161,286 options
(0.0008%)
---
Total 1,539,178 (0.00104%)
---
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security: Long Short
---
Number (%) Number (%)
---
(1) Relevant securities
---
(2)
Derivatives
(other
than
options)
---
(3) Options and agreements to purchase/sell
---
Total
---
3.
DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 5)
---
Withholding of common
shares to satisfy tax
obligations
56,950 common shares $0
---
(b) Derivatives transactions (other than options transactions)
---
Product name,
Nature of transaction
Number of relevant securities
Price per unit
e.g.
CFD
(Note 6)
(Note 7)
(Note 5)
---
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing,
selling, Number
of
name, securities
Exercise Type,
e.g. Expiry Option
money
e.g. to
which
call the
option
option
purchasing,
price
American,
date
paid/received
varying etc.
relates (Note 7)
European etc.
per unit (Note 5)
---
(ii) Exercising
Product
name,
Number of securities
Exercise price per unit (Note 5)
e.g.
call
option
---
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature
of
Details Price
per
transaction unit
(Note 8)
(if applicable) (Note 5)
---
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
---
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If none, this should be stated.
---
Is a Supplemental Form 8 attached? (Note 9)
YES/NOSQRT
Date of disclosure
27 March 2020
--- ---
Contact
name
Steven L. Scrogham
--- ---
Telephone
number
847-938-6166
--- ---
Name
of
offeree/offeror
with
which
acting
in
concert
AbbVie Inc.
--- ---
Specify category and nature of acting in concert status Director of AbbVie Inc.
--- ---
View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-301031478.html
SOURCE AbbVie
